Multicenter prospective observational study of Antineoplastic cardiotoxicity and Chemotherapy-related Cardiac Dysfunction

Multicenter prospective observational study of Antineoplastic cardiotoxicity and Chemotherapy-related Cardiac Dysfunction - Multicenter prospective observational study of Antineoplastic cardiotoxicity and Chemotherapy-related Cardiac Dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043889

Enrollment

150

Registered

2021-04-12

Start date

2021-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological tumors treated with CHOP therapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 20 years of age or older who are scheduled to receive chemotherapy (CHOP, R-CHOP, G-CHOP) including anthracycline anticancer agents at the Department of Hematology of Toranomon Hospital, Kameda General Hospital, or St. Luke's International Hospital Patients with no history of cardiac disease (heart failure, coronary artery disease, cardiomyopathy, arrhythmia, post-valvular surgery, post-implantation cardiac device, congenital heart disease) Translated with www.DeepL.com/Translator (free version)

Exclusion criteria

Exclusion criteria: Patients with LVEF <50% diagnosed by echocardiography Those judged unsuitable by the physician in charge

Design outcomes

Primary

Measure	Time frame
Onset of CTRCD Changes in echocardiographic findings before and after the start of chemotherapy	—

Secondary

Measure	Time frame
Development of heart failure Cardiovascular events All deaths Cardiovascular death	—

Countries

Japan

Contacts

Public ContactChinatsu Komiyama

Toranomon Hospital Cardiovascular Center

ckomiyama88@gmail.com03-3588-1111

Outcome results